Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Dr Raffaele Baffa Is Appointed CARsgen Chief Medical Officer

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Dr Raffaele Baffa has been appointed as the Chief Medical Officer (“CMO”) of the Company, responsible for overseeing the global clinical development strategies and operations for the Company’s innovative pipeline product candidates.

Dr Raffaele Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited.

Dr. Baffa has rich experiences in pharmaceutical industry and research institutes, taking various leadership positions in multi-national corporations and biotech companies. Prior to joining CARsgen, Dr. Baffa served as Chief Medical Officer and Executive Vice President of Research & Development at Ziopharm Oncology (NASDAQ: ZIOP), which was rebranded to Alaunos in January 2022. (NASDAQ: TCRT). Prior to Ziopharm Oncology, Dr. Baffa was Head of Research & Development and Chief Medical Officer in Medisix Therapeutics, a company focused on developing novel immune cell therapies. Dr. Baffa was the Vice President, Therapeutic Area Head of Oncology, Global Clinical Development of Shire Pharmaceuticals, and following the acquisition of the oncology division by Servier Pharmaceuticals, Dr. Baffa served as the Chief Medical Officier of Servier Pharmaceuticals. Dr. Baffa has also held leadership positions at well-known pharmaceutical companies, such as Pfizer and Sanofi.

Dr. Baffa earned an M.D. from University of Padova, School of Medicine and a Ph.D. in biology and molecular pathology from University of Parma in Italy.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited, said, “We warmly welcome Dr. Baffa to join CARsgen. Dr. Baffa is a medical professional and industry veteran with extensive experiences in clinical development and translational sciences in the field of oncology and cellular immunotherapy. Dr. Baffa brings a wealth of clinical, medical, and leadership experiences from multinational corporations and biotechnology companies. Dr. Baffa joins us at an exciting time as the clinical trials for both CT053 and CT041 are progressing in North America and being explored in other territories. Dr. Baffa’s joining will further accelerate the global clinical development of our innovative product candidates.”

Dr. Raffaele Baffa, Chief Medical Officer of CARsgen Therapeutics Holdings Limited, said, “I am very excited to join CARsgen. As one of the leading companies in cell therapies globally, CARsgen has developed a rich and differentiated product pipeline and a suite of exciting technology platforms such as THANK-uCAR® for allogeneic CAR T and LADAR® for precise targeting. CARsgen has also shown big ambitions with continuous investment for the global market, such as the establishment of the manufacturing facility in the United States. I look forward to working closely with colleagues in CARsgen and external partners to accelerate CARsgen’s global clinical development and bring more innovative products to cancer patients.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine